Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
 - EconoTimes)
NEW ORLEANS, Oct. 17, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 24, 2017 to file lead plaintiff applications in a securities class action lawsuit against PetMed Express, Inc. (NASDAQ:PETS), if they purchased the Company’s securities between May 8, 2017, and August 23, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of Florida.
Get Help
PetMed Express investors should visit us at https://www.claimsfiler.com/cases/view-petmed-express-inc-securities-litigation-1 or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
PetMed Express and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 23, 2017, it was revealed through a comprehensive report issued by Aurelius Value entitled “PetMed: Exploiting America’s Opioid Epidemic” that PetMed Express had targeted its products, painkillers especially addictive synthetic opiates, to opioid users through the aggressive use of Google ads and other online marketing services, potentially facilitating the abuse of opiates as “human crossover painkillers.”
On this news, the price of PetMed Express shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
